Methyl dehydroabietate

Cat. No.: HY-W109613 Purity: 99.89%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Methyl dehydroabietate is an orally active resin acid. Methyl dehydroabietate disrupts microbial cell walls and exhibits significant antibacterial activity. Methyl dehydroabietate induces the expression of PPARα in the liver and PPARγ in adipose tissue, and promotes adipocyte differentiation. Methyl dehydroabietate improves insulin resistance, reduces TNFα levels, and alleviates adipocyte hypertrophy and hepatic steatosis in obese mice. Methyl dehydroabietate can be used in research related to obesity, insulin resistance and hepatic steatosis.

For research use only. We do not sell to patients.

Methyl dehydroabietate Chemical Structure

CAS No. : 1235-74-1

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	Get quote
1 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All PPAR Isoform Specific Products:

View All Isoforms

PPARα PPARβ/δ PPARγ PPAR PPARδ

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A549	GI₅₀	15 μM Compound: 8	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 30840453]
A549	IC₅₀	41.25 μM Compound: 6	Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human A549 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
HBL-100	GI₅₀	19 μM Compound: 8	Antiproliferative activity against human HBL100 cells Antiproliferative activity against human HBL100 cells	[PMID: 30840453]
HeLa	GI₅₀	15 μM Compound: 8	Antiproliferative activity against human HeLa cells Antiproliferative activity against human HeLa cells	[PMID: 30840453]
HeLa	IC₅₀	28 μg/mL Compound: 3, methyl dehydroabietate	Cytotoxicity against human HeLa cells after 48 hrs by MTT assay Cytotoxicity against human HeLa cells after 48 hrs by MTT assay	[PMID: 19892441]
Jurkat	IC₅₀	21 μg/mL Compound: 3, methyl dehydroabietate	Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay Cytotoxicity against human Jurkat cells after 48 hrs by MTT assay	[PMID: 19892441]
PC-3	IC₅₀	37.7 μM Compound: 6	Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human PC3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SK-OV-3	IC₅₀	51.31 μM Compound: 6	Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay Cytotoxic activity against human SKOV3 cells assessed as reduction in cell viability after 72 hrs by SRB assay	[PMID: 28011223]
SW1573	GI₅₀	22 μM Compound: 8	Antiproliferative activity against human SW1573 cells Antiproliferative activity against human SW1573 cells	[PMID: 30840453]
T47D	GI₅₀	16 μM Compound: 8	Antiproliferative activity against human T47D cells Antiproliferative activity against human T47D cells	[PMID: 30840453]
Vero	IC₅₀	20 μg/mL Compound: 18	Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells Concentration required for 50% inhibition of herpes simplex virus 2(HSV-2) using standard plaque reduction assay in vero cells	10.1016/S0960-894X(01)80236-5
Vero	IC₅₀	36 μg/mL Compound: 3, methyl dehydroabietate	Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay Cytotoxicity against african green monkey Vero cells after 48 hrs by MTT assay	[PMID: 19892441]
WiDr	GI₅₀	10 μM Compound: 8	Antiproliferative activity against human WiDr cells Antiproliferative activity against human WiDr cells	[PMID: 30840453]

In Vitro

Methyl dehydroabietate exhibits potent antibacterial activity against a wide range of Gram-positive and Gram-negative bacteria, as well as against certain antibiotic-resistant microorganisms (e.g., methicillin-resistant Staphylococcus aureus, enterococci, etc.); it also demonstrates antifungal activity against common dermatophytes (i.e., the primary pathogens responsible for fungal skin diseases)^[1].
Methyl dehydroabietate (10-50 μM; 13-14 days) promotes adipocyte differentiation in 3T3-L1 preadipocytes in vitro in a dose-dependent manner, with significant induction observed at 50 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Differentiation Assay^[2]

Cell Line:	mouse 3T3-L1 preadipocytes
Concentration:	10 μM; 50 μM
Incubation Time:	13 days (10 μM); 14 days (50 μM)
Result:	Increased neutral lipid accumulation significantly relative to vehicle control at 50 μM. Exhibited significantly higher differentiation potency than dehydroabietic acid at 50 μM. Did not produce a statistically significant change in adipocyte differentiation at 10 μM.

In Vivo

Methyl dehydroabietate (50 mg/kg; p.o.; daily; for 8 consecutive weeks) significantly reduces body weight, epididymal adipose tissue weight, and plasma levels of glucose, insulin, leptin and TNFα in obese male C57BL/6J mice induced by high-fat diet (HFD), while alleviates adipocyte hypertrophy and hepatic steatosis by regulating the expression of PPARα and PPARγ^[2].
Methyl dehydroabietate (50 mg/kg; p.o.; daily; for 8 weeks) exerts no significant effects on body weight, organ weight, or plasma metabolic/inflammatory biomarkers in healthy male C57BL/6J mice, but upregulates the protein expression of PPARα in the liver and PPARγ in adipose tissue, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J (male, 5 weeks old, 18-21 g, HFD-induced obesity)^[2]
Dosage:	50 mg/kg
Administration:	p.o.; once daily; 8 weeks
Result:	Reduced final mean body weight to 27.6 g, significantly lower than the HFD-only group's 31.0 g. Reduced mean epididymal adipose tissue weight to 0.99 g, significantly lower than the HFD-only group's 1.44 g. Significantly reduced HFD-induced elevated plasma glucose, insulin, leptin, and TNFα levels. Reduced HFD-induced adipocyte hypertrophy in epididymal adipose tissue and decreased the number of large hepatic lipid droplets (attenuated hepatic steatosis). Increased PPARγ and aP2 protein expression in epididymal adipose tissue, increased PPARα protein expression in the liver, and reduced HFD-induced perilipin-2 protein expression in the liver.

Animal Model:	C57BL/6J (male, 5 weeks old, 18-21 g, healthy)^[2]
Dosage:	50 mg/kg
Administration:	p.o.; once daily; 8 weeks
Result:	Resulted in a final mean body weight of 25.4 g, which was not significantly different from the normal diet control group's 25.3 g. Showed mean liver weight of 0.87 g (slightly increased vs. control's 0.82 g), mean kidney weight of 0.26 g, and mean epididymal adipose tissue weight of 0.24 g; none of these differed significantly from control values. Plasma glucose, insulin, leptin, and TNFα levels were not significantly different from normal diet control values. Adipocyte size and liver morphology were comparable to normal diet control mice. Increased PPARγ and aP2 protein expression in epididymal adipose tissue and increased PPARα protein expression in the liver relative to normal diet control mice.

Molecular Weight

314.46

Formula

C₂₁H₃₀O₂

CAS No.

1235-74-1

Appearance

Solid

Color

White to off-white

SMILES

O=C([C@]1(C)CCC[C@]2(C)C3=C(CC[C@@]12[H])C=C(C(C)C)C=C3)OC

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (159.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.1801 mL	15.9003 mL	31.8005 mL
5 mM	0.6360 mL	3.1801 mL	6.3601 mL
10 mM	0.3180 mL	1.5900 mL	3.1801 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.95 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.89%

Select Batch:

Data Sheet (277 KB) SDS (254 KB)

COA (247 KB) HNMR (262 KB) LCMS (90 KB) OR (248 KB)

Handling Instructions (2659 KB)

References

[1]. Burčová Z, et al. Antibacterial and antifungal activity of phytosterols and methyl dehydroabietate of Norway spruce bark extracts. J Biotechnol. 2018;282:18-24. [Content Brief]

[2]. Yoshioka H, et al. Methyl dehydroabietate counters high fat diet-induced insulin resistance and hepatic steatosis by modulating peroxisome proliferator-activated receptor signaling in mice. Biomed Pharmacother. 2018;99:214-219.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.1801 mL	15.9003 mL	31.8005 mL	79.5014 mL
	5 mM	0.6360 mL	3.1801 mL	6.3601 mL	15.9003 mL
	10 mM	0.3180 mL	1.5900 mL	3.1801 mL	7.9501 mL
	15 mM	0.2120 mL	1.0600 mL	2.1200 mL	5.3001 mL
	20 mM	0.1590 mL	0.7950 mL	1.5900 mL	3.9751 mL
	25 mM	0.1272 mL	0.6360 mL	1.2720 mL	3.1801 mL
	30 mM	0.1060 mL	0.5300 mL	1.0600 mL	2.6500 mL
	40 mM	0.0795 mL	0.3975 mL	0.7950 mL	1.9875 mL
	50 mM	0.0636 mL	0.3180 mL	0.6360 mL	1.5900 mL
	60 mM	0.0530 mL	0.2650 mL	0.5300 mL	1.3250 mL
	80 mM	0.0398 mL	0.1988 mL	0.3975 mL	0.9938 mL
	100 mM	0.0318 mL	0.1590 mL	0.3180 mL	0.7950 mL